When patients learn about ketamine therapy for depression, one of the first questions is often about the route of administration. Intravenous (IV) ketamine infusions have been studied since the early 2000s, while oral and sublingual ketamine have gained traction as a more accessible and affordable option. Both deliver the same medication but differ in bioavailability, cost, convenience, and clinical setting. Here is what you should know.
| Factor | Oral/Sublingual Ketamine | IV Ketamine Infusion |
|---|---|---|
| How it works | Absorbed through oral mucosa or GI tract; same NMDA receptor mechanism | Delivered directly into the bloodstream; same NMDA receptor mechanism |
| Speed of relief | Many patients report improvement within days; onset during session is gradual | Effects may begin during the infusion; some patients report improvement after first session |
| Administration | At home with telemedicine physician support; tablet or troche dissolved under the tongue | In-clinic; requires IV line placement and monitoring by medical staff for ~40-60 minutes |
| Cost | ~$350/appointment + $50-150/mo medication at Isha Health | $400-800 per infusion; initial course of 6 sessions = $2,400-4,800+ |
| FDA status | Off-label use; ketamine is FDA-approved only as an anesthetic | Off-label use; ketamine is FDA-approved only as an anesthetic |
| Side effects | Nausea, dissociation, dizziness, bitter taste; generally milder due to lower bioavailability | Dissociation, nausea, elevated blood pressure, dizziness; effects may be more pronounced |
| Evidence level | Growing body of evidence including large retrospective studies and emerging RCTs | More established clinical trial evidence; most early ketamine research used IV route |
Bioavailability: IV ketamine delivers nearly 100% of the medication into the bloodstream, while oral/sublingual administration has a bioavailability of approximately 20-30%. This means oral doses are adjusted accordingly. While IV delivery is more precise, recent studies have demonstrated that oral ketamine at appropriate doses can produce clinically meaningful antidepressant effects.
Convenience and accessibility: IV infusions require visiting a specialized clinic, typically 2-3 times per week during the initial phase. Each session involves IV placement and 40-60 minutes of monitored infusion, plus recovery time. Oral ketamine can be taken at home under telemedicine supervision, eliminating travel time and clinic visits. This is particularly relevant for patients in areas without nearby infusion clinics.
Cost considerations: IV infusion clinics typically charge $400-800 per session, and an initial course of 6 sessions can total $2,400-4,800 or more. At-home oral ketamine through Isha Health involves physician appointments at $350 each plus $50-150 per month for compounded medication, which is generally a significantly lower total cost over a treatment course.
Metabolite profiles: Oral ketamine produces higher levels of norketamine (a metabolite) relative to ketamine itself, compared to IV administration. Some researchers have suggested that norketamine may contribute to antidepressant effects through its own mechanisms, though this is still an active area of investigation.
IV ketamine has higher bioavailability, but growing evidence suggests oral ketamine can also produce meaningful antidepressant effects. Recent large retrospective studies have shown significant symptom improvement with oral ketamine. The best route depends on individual factors.
Yes. Oral and sublingual ketamine can be prescribed for at-home use under physician supervision via telemedicine. Isha Health provides at-home ketamine therapy with ongoing clinical support. IV infusions must be administered in a clinical setting.
IV infusions typically cost $400-800 per session, with 6 sessions commonly recommended initially. At-home oral ketamine through Isha Health is $350 per appointment plus $50-150/month for medication. See our pricing page for current details.
No. Neither oral ketamine nor IV ketamine is FDA-approved for depression. Ketamine is FDA-approved as an anesthetic and prescribed off-label for depression. Only esketamine (Spravato), an intranasal formulation, has received FDA approval specifically for treatment-resistant depression.
Interested in at-home oral ketamine therapy?
Speak with one of our physicians to find out if at-home ketamine is right for you.
Check Appointment Availability